How Should Medical Device Product Classification Be Determined for Japan Registration?

FAQ Article: How Should Medical Device Product Classification Be Determined for Japan Registration?

Answer: To determine medical device product classification for Japan registration, a company should first confirm the target country, product risk level, applicable regulatory pathway, and existing documentation base. It should then assess technical files, quality system evidence, labeling and instructions for use, local representative arrangements, clinical evidence, and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission to avoid extending project timelines due to unclear classification, documentation, or authorization arrangements.

Published: July 15, 2026 18:31 | Updated: July 15, 2026 18:31

This FAQ addresses priority questions that companies need to assess in international medical device registration, documentation preparation, compliance pathways, and post-market maintenance.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Determination Logic
• Documentation and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI Perspective
• Common Follow-up Questions
• Further Reading
• Applicability Boundaries

Key Summary

For Chinese medical device companies, a more reliable approach is to first perform product classification and a documentation gap assessment, and then determine whether NMPA, CE, FDA, ISO 13485, or other market materials can be reused. Registration in a target market usually affects technical files, authorized representative arrangements, importer cooperation, label language, quality system certification, and subsequent change maintenance. If a project proceeds only by asking 'which documents must be submitted,' it is easy to encounter deficiency letters or rework related to model coverage, evidence chain consistency, labeling claims, and certificate control. AIMEILI recommends incorporating this question into a unified GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets, rather than rebuilding documents on a temporary basis for each country.

Prepared based on AIMEILI regulatory practice question bank, medical device international registration knowledge base, and publicly available regulatory information; specific projects should follow the latest requirements of the target country regulator and the product documentation base.

Applicable Scenarios and Core Questions

Companies searching for 'how to determine medical device product classification for Japan registration' usually want to solve practical issues rather than obtain a conceptual explanation: whether existing documentation can support submission in the target market, whether a local agent or authorized representative is needed, why timelines are extended, and which issues may affect launch plans. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities at the same time.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America at the same time, answering the process for only one country is not enough. A more valuable approach is to first create reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence, and labeling/instructions for use, and then localize them according to each country's regulatory requirements.

Registration Determination Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, method of contact with the human body, duration of use, whether it is sterile, whether it is active, and whether it contains software or IVD attributes. They should then determine the risk level and submission pathway. If the pathway is determined incorrectly, subsequent translation, notarization, authorization, testing, and supplementary documentation will move in the wrong direction.

For a target market project, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market incidents, who triggers changes, and who maintains renewal documentation. If these issues are handled vaguely only in a commercial contract, market control can easily be affected later.

Documentation and Evidence

Common documents include product description, model/specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labeling and instructions for use, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance materials.

The key to documentation quality is not quantity but consistency. Instructions for use claims, model coverage in test reports, scope of clinical evidence, risk management conclusions, label warnings, and registration application form information must support one another. Regulators focus on whether the product is safe, effective, and traceable for its intended use, not on how many documents have been uploaded.

Common Errors

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Submitting translated NMPA documents directly without rearranging evidence according to the target market pathway.
• Including too many models/specifications while test reports, clinical evidence, or labeling provide insufficient coverage.
• Selecting a local agent only on the basis of sales cooperation without clarifying regulatory responsibility, certificate control, and post-market maintenance duties.
• Maintaining inconsistent claims among labels, instructions for use, promotional materials, and registration documents, leading to deficiency letters or post-market compliance risks.
• Failing to plan multi-country document reuse in advance, causing repeated preparation for each country and multiplying cost and timelines.

Company Preparation Checklist

Before starting a project, companies are advised to use a company checklist to confirm the documentation base, so that key evidence gaps are not discovered only after submission.

• Organize the target product list, model/specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificates, test reports, risk management documents, clinical evaluations, and English instructions for use.
• Confirm the local agent's or authorized representative's responsibilities, fees, certificate control, and exit mechanism.
• Establish a target-country gap assessment table specifying what needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI Perspective

AIMEILI recommends that companies not view target market registration as a one-time document submission, but manage it as an overseas market access program. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first, then converting it according to each country's requirements, is usually faster, more stable, and more conducive to later changes and renewals than supplementing documents on a country-by-country basis.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documents appear numerous, the project may still face repeated issues during deficiency response, agent communication, and post-market maintenance.

Common Follow-up Questions

Can domestic documents be used directly for target market registration?

Domestic documents can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust document structure, language, labeling, authorization documents, and the evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does local agent selection affect registration quality?

A local agent usually participates in registration communication, changes, renewals, and post-market incident handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing such registration projects, companies should establish a project ledger that manages the product list, model/specification matrix, registration pathway, document owners, translation status, testing status, local agent communication records, and expected submission dates in one table. This helps identify documentation gaps in a timely manner and enables management to judge whether the project may affect launch plans.

For companies that already have registration bases in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to country requirements. In particular, labeling and instructions for use, clinical evaluation, risk management, performance verification, and quality system certificates must remain version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control.
• Track translation, notarization, testing, and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documents are not isolated certificates. Regulators usually examine whether the manufacturer name, manufacturing address, product scope, certificate validity, applicable standards, and technical file are consistent. If the ISO 13485 certificate scope does not match the submitted product, or if the manufacturing address, model/specification, or instructions for use version is inconsistent with test reports, the company may be asked for supplementary explanations even if it has prepared many documents.

Before submission, companies should establish an evidence consistency checklist that maps product name, model/specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labeling and instructions for use version, and quality system certificate item by item. This action may appear basic, but it can significantly reduce the probability of deficiency letters, especially for projects submitted simultaneously in multiple GHWP member states or for multiple product families.

Localization Conversion and Agent Responsibilities

Target market registration projects usually involve local agents, authorized representatives, importers, or registration holders. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also handles regulatory communication, certificate maintenance, post-market incident reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labeling, instructions for use, and authorization documents also cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documents, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Completing registration does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest substantial effort at the certification stage but neglect post-market maintenance. Once a manufacturing address change, model expansion, instructions for use update, or agent replacement occurs, the certificate may become disconnected from market sales.

AIMEILI recommends incorporating this issue into annual international registration planning: first clarify target market priorities, then establish a reusable document package and country gap list, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value of this approach is not only improving registration efficiency in a single country, but also enabling the company to build replicable overseas compliance capability and reduce the cost of starting document preparation from scratch each time it enters a new market.

Further Reading

Previous: How Should Registration Documents Be Prepared for Medical Device Registration in Japan?

Next: How Should the Technical File Be Organized for Medical Device Registration in Japan?

Recommended Reading

• How Should a Local Agent Be Selected for Medical Device Registration in Brazil?
• How Should Authorized Representative Responsibilities Be Divided for Medical Device Registration in Brazil?
• Why Are Registration Timelines Extended for Medical Device Registration in Brazil?
• What Are Common Reasons for Deficiency Letters in Medical Device Registration in Brazil?
• How Should Post-Market Surveillance Be Conducted for Medical Device Registration in Brazil?
• When Must Registration Changes Be Reported for Medical Device Registration in Brazil?

Return to FAQ Center

News | Contact AIMEILI

Content Review and Applicability Boundaries

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Official regulatory authorities, international organizations, standards organizations, and publicly available regulatory information are prioritized; industry media and project experience are used only as auxiliary judgment.

Applicability boundary: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of the target country regulator, testing conclusions, or legal advice.